Abstract

The flow cytometry core will isolate from the marrow of normal controls and patients with myelodysplastic disorders, cell populations enriched for pluripotent hematopoietic stem cells (PHSC), hematopoietic progenitor cells (HPC) and more differentiated precursor cells. Furthermore, subpopulations of CD34plus which are enriched for CFU-Gm (CD34plusCD64plus), BFU-E (CD34hiCD71hiCD64-) or CFU-E (CD34loCD71hiCD64-) will be isolated from the marrow of normal controls and patients with myelodysplastic disorders. This core will perform in vitro assays to detect pluripotent hematopoietic stem cells and hematopoietic progenitor cells. These assays will include long-term bone marrow cultures which detect cobblestone area forming cells and clonal assays in semisolid media to detect HPC. This core will also provide advanced training to investigators that require access to flow cytometry or assays for hematopoietic progenitor and stem cells.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
3P01CA075606-05S1
Application #
6659201
Study Section
Project Start
2002-06-01
Project End
2003-05-31
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
5
Fiscal Year
2002
Total Cost
$312,755
Indirect Cost

  Institution

Name
Rush University Medical Center
Department
Type
DUNS #
City
Chicago
State
IL
Country
United States
Zip Code
60612

  Publications

Raza, A; Candoni, A; Khan, U et al. (2004) Remicade as TNF suppressor in patients with myelodysplastic syndromes. Leuk Lymphoma 45:2099-104
Candoni, Anna; Silvestri, Federico; Buonamici, Silvia et al. (2004) Targeted therapies in myelodysplastic syndromes: ASH 2003 review. Semin Hematol 41:13-20
Raza, Azra; Buonamici, Silvia; Lisak, Laurie et al. (2004) Arsenic trioxide and thalidomide combination produces multi-lineage hematological responses in myelodysplastic syndromes patients, particularly in those with high pre-therapy EVI1 expression. Leuk Res 28:791-803
Huang, X K; Meyer, P; Li, B et al. (2003) The effects of the farnesyl transferase inhibitor FTI L-778,123 on normal, myelodysplastic, and myeloid leukemia bone marrow progenitor proliferation in vitro. Leuk Lymphoma 44:157-64
Gladstone, Betty; Sivaraman, Smitha; Galili, Naomi et al. (2003) A novel method for single cell detection of in situ telomerase or histone H3 in combination with clonal analysis by FISH. Leuk Res 27:529-37
Reddy, Poluru L; Shetty, Vilasini T; Dutt, Diya et al. (2002) Increased incidence of mitochondrial cytochrome c-oxidase gene mutations in patients with myelodysplastic syndromes. Br J Haematol 116:564-75
Allampallam, Krishnan; Shetty, Vilasini; Mundle, Suneel et al. (2002) Biological significance of proliferation, apoptosis, cytokines, and monocyte/macrophage cells in bone marrow biopsies of 145 patients with myelodysplastic syndrome. Int J Hematol 75:289-97
Shetty, Vilasini; Hussaini, Seema; Alvi, Sairah et al. (2002) Excessive apoptosis, increased phagocytosis, nuclear inclusion bodies and cylindrical confronting cisternae in bone marrow biopsies of myelodysplastic syndrome patients. Br J Haematol 116:817-25
Raza, A; Meyer, P; Dutt, D et al. (2001) Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood 98:958-65
Zorat, F; Shetty, V; Dutt, D et al. (2001) The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes. Br J Haematol 115:881-94

Showing the most recent 10 out of 40 publications